Advancements in resistance to Tamoxifen

Tamoxifen has been for over 20 years the main drug used against breast cancer, as it blocks estrogen activity, that is, the hormones that drive the growth of cancer cells. However, many women are resistant to the drug. On November last year, Antoni Hurtado, the Spanish researcher at the Cancer Research UK-Cambridge Research Insitute, led a study published on Nature that discovered the molecular basis that explains why Tamoxifen is or is not effective. This study opened the way to the prediction of the response of patients to this drug, and thus to the consideration of new, alternative treatments for those patients in whom it does not work.

Mr. Hurtado will speak on February 26th at 13:00 pm on the factors that affect resistance to Tamoxifen. The seminar, “Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen”, will be made on Floor 11 of the General Area of the Vall d’Hebron University Hospital. These seminars are organized by the Vall d’Hebron Research Institute and the Oncology Service of this same hospital.

Related Posts